|
SEATTLE – (April 15, 2019) –Arzeda, the Protein Design Company™, has been featured in GeekWire: Inside Arzeda's synthetic biology lab, where industrial ingredients are brewed like beer.
3 Comments
 SEATTLE – (April 6, 2019) –Arzeda, the Protein Design Company™, has been featured in the April 6th issue of The Economist's Technology Quarterly on synthetic biology.
Arzeda Ranks #5 in Biofuels Digest’s Annual “Hottest Technologies in the Advanced Bioeconomy” List11/14/2018 Arzeda continues to climb the annual rankings of world’s most widely read biofuels and biobased chemicals daily journal
SEATTLE and SAN FRANCISCO – (November 14, 2018) –Arzeda, the Protein Design Company™, has been recognized for the third time as among the top companies in the advanced bioeconomy in the annual rankings by Biofuels Digest, the world’s most widely-read bioeconomy daily. Arzeda was ranked Number 5 in this year’s 40 Hottest Technologies in the Advanced Bioeconomy list, one step above its number 6 ranking in 2017. Arzeda ranked number 27 on the list in 2016. SEATTLE and SAN FRANCISCO – (October 2, 2018) –Arzeda, The Protein Design Company™, and BP announced a collaboration to develop a process for producing a renewable chemical with broad applications.
Arzeda and TeselaGen Partner to Advance Biodesign Technologies for Industrial Biotechnology10/3/2017  SEATTLE and SAN FRANCISCO – (October 3, 2017) –Arzeda Corp, “The Protein Design Company™,” and TeselaGen Biotechnology Inc., a software company providing automated DNA design solutions with it’s Synthetic Evolution™ software platform, today announced that Arzeda will license TeselaGen’s proprietary cloud-based informatics solution and collaborate to extend TeselaGen’s state-of-the-art biological design automation platform.
 Technology scale-up will unlock production of proteins that create sustainable stain-resistant paint, stronger Plexiglas, next-generation sweeteners, and purpose-built molecules that don’t yet exist
SEATTLE, (July 20, 2017) Arzeda, The Protein Design Company™, today announced that it had raised $12 million in a Series A round of funding led by OS Fund and including Bioeconomy Capital and Sustainable Conversion Ventures, as well as a follow-on investment from Arzeda’s seed investor, WRF Capital. Arzeda’s board will be expanded to include Jeff Klunzinger, Co-Founder at OS Fund.  SEATTLE (April 20, 2016) Gen9 and Arzeda today announced an agreement for the supply of megabase quantities of synthetic DNA that will enable Arzeda to accelerate development of novel molecules for its own products as well as those of its partners. The collaboration is part of Gen9’s MAP program, designed to provide industrial users of synthetic DNA with access to game-changing economics for synthetic DNA.
 SEATTLE and EMERYVILLE, Calif. (March 21, 2016) Zymergen and Arzeda announced today a multi-year agreement to develop strains and processes to manufacture novel, high utility molecules and materials utilizing Arzeda’s pathway and enzyme design and Zymergen’s strain construction capabilities.
 Arzeda will help further develop Stratos’ “Sequencing by Design” technology for rapid single molecule DNA sequencing
SEATTLE, November 11, 2015 – Biotechnology company Arzeda announced today an Agreement with Stratos Genomics to assist development of novel enzymes supporting Stratos’ DNA sequencing technology. |